IPP Bureau
CIVCO Radiotherapy to Unveil TotalRT All in One Solution at ESTRO 2022
By IPP Bureau - May 02, 2022
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
World’s first AI software for detecting pancreatic disease on the horizon
By IPP Bureau - May 02, 2022
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
By IPP Bureau - May 02, 2022
Avacc 3 has significant advantages over existing whooping cough vaccines
StanPlus appoints Gurjit Singh as COO and Founding Member
By IPP Bureau - May 02, 2022
He will be leading the business, operations, P&L, and growth strategy for StanPlus
USFDA concludes inspection of Shilpa Medicare with four observations
By IPP Bureau - May 02, 2022
The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as an alternate testing laboratory
Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools
By IPP Bureau - May 02, 2022
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
NHA enlists Pristyn Care as health tech partner for Ayushman Bharat Digital Mission
By IPP Bureau - May 02, 2022
ABDM is a critical integration that leverages an open, interoperable, standards-based digital system that is secure, and maintains confidentiality and privacy of health-related personal information
Dr. Mansukh Mandaviya to chair a three-day health meet at Kevadia in Gujarat
By IPP Bureau - May 02, 2022
State Ministers of Health and Medical Education to Participate in the meeting from 5th to 7th May
Sage Therapeutics and Biogen initiate rolling submission of New Drug Application for Zuranolone
By IPP Bureau - May 02, 2022
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
By IPP Bureau - May 01, 2022
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Moderna finalizes plan for long-term strategic partnership with Canada
By IPP Bureau - May 01, 2022
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts
By IPP Bureau - May 01, 2022
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Global Cord Blood Corp acquires Cellenkos to advance cell therapy market
By IPP Bureau - May 01, 2022
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Inmagene receives USFDA's IND clearance for ox40 antagonist
By IPP Bureau - May 01, 2022
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Genome Insight draws US $ 23 million in Series B Funding
By IPP Bureau - May 01, 2022
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
